JW (Cayman) Therapeutics Co (HKSE:02126) Dividends per Share : HK$0.00 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Dividends per Share?

JW (Cayman) Therapeutics Co's dividends per share for the six months ended in Dec. 2023 was HK$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, JW (Cayman) Therapeutics Co's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

JW (Cayman) Therapeutics Co Dividends per Share Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Dividends per Share Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividends per Share	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of JW (Cayman) Therapeutics Co's Dividends per Share

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Dividend Yield % falls into.

JW (Cayman) Therapeutics Co Dividends per Share Calculation

Dividends paid to per common share.

JW (Cayman) Therapeutics Co (HKSE:02126) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

JW (Cayman) Therapeutics Co's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.545
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

JW (Cayman) Therapeutics Co Dividends per Share Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines